title: Severe acute respiratory syndrome coronavirus elicits a weak interferon response compared to traditional interferon-inducing viruses.
abstract: The aim of the present study is to investigate changes of interferon (IFN) production occurring over the first 48 h after infection of peripheral blood mononuclear cells (PBMCs) with severe acute respiratory syndrome (SARS) coronavirus (CoV) and to compare these changes to those induced by well-established IFN-inducing viruses, such as vesicular stomatitis (VSV) and Newcastle viruses (NDV). Experiments have been carried out using PBMCs of 10 different healthy donors. The results showed that the antiviral activity of IFN contained in the supernatant of SARS-CoV-infected PBMCs was lower than those induced by VSV and NDV. Consequently, SARS-CoV induces a lower synthesis of IFN-alpha, -beta and -gamma compared to VSV and NDV. Characterization of the profile of IFN-alpha subtypes genes expression in SARS-CoV-infected PBMCs demonstrated that the level of IFN-alpha2 and -6 subtypes were higher compared to other IFN-alpha subtypes namely, IFN-alpha5, -8, -10, -13/1, -17, and -21. In conclusion, SARS-CoV induces IFNs to a less extent compared to VSV and NDV, thus suggesting that the IFN system does play a limited role in early host defense against SARS-CoV infection.
authors.affiliation: Department of Experimental Medicine - Virology Section, Sapienza University of Rome, Rome, Italy. carolina.scagnolari@uniroma1.it
authors.forename: Carolina
authors.initials: C
authors.lastname: Scagnolari
authors.forename: Simona
authors.initials: S
authors.lastname: Trombetti
authors.forename: Simona
authors.initials: S
authors.lastname: Cicetti
authors.forename: Silvia
authors.initials: S
authors.lastname: Antonelli
authors.forename: Carla
authors.initials: C
authors.lastname: Selvaggi
authors.forename: Lorena
authors.initials: L
authors.lastname: Perrone
authors.forename: Michela
authors.initials: M
authors.lastname: Visca
authors.forename: Sara
authors.initials: S
authors.lastname: Romano
authors.forename: Guido
authors.initials: G
authors.lastname: Antonelli
mesh_terms: D002478:Cells, Cultured; D020869:Gene Expression Profiling; D006801:Humans; D007372:Interferons / Q000096:biosynthesis / Q000276:immunology*; D007963:Leukocytes, Mononuclear / Q000276:immunology* / Q000821:virology*; D009522:Newcastle disease virus / Q000276:immunology; D045473:Severe acute respiratory syndrome-related coronavirus / Q000276:immunology*; D018116:Vesiculovirus / Q000276:immunology
chemical_list: D007372:Interferons
references.citation: Biochem Biophys Res Commun. 1983 Apr 29;112(2):537-46
references.pmid: 6303322
references.citation: Virol J. 2006 Mar 29;3:17
references.pmid: 16571117
references.citation: J Interferon Res. 1993 Dec;13(6):423-6
references.pmid: 8151137
references.citation: PLoS Pathog. 2007 Aug 10;3(8):e112
references.pmid: 17696609
references.citation: Biochimie. 2007 Jun-Jul;89(6-7):836-42
references.pmid: 17336442
references.citation: J Viral Hepat. 2001 Mar;8(2):103-10
references.pmid: 11264730
references.citation: Virology. 2005 Oct 10;341(1):163-9
references.pmid: 16095648
references.citation: Biochimie. 2007 Jun-Jul;89(6-7):713-8
references.pmid: 17544197
references.citation: J Interferon Cytokine Res. 1996 Dec;16(12):1027-33
references.pmid: 8974005
references.citation: J Virol. 2005 May;79(10):6180-93
references.pmid: 15858003
references.citation: Virology. 2007 Apr 25;361(1):18-26
references.pmid: 17316733
references.citation: Arch Biochem Biophys. 1981 Aug;210(1):319-29
references.pmid: 6170263
references.citation: J Gen Virol. 2006 Jul;87(Pt 7):1953-1960
references.pmid: 16760397
references.citation: Hepatol Res. 2002 Oct;24(2):99
references.pmid: 12270738
references.citation: J Virol. 2005 Jun;79(12):7819-26
references.pmid: 15919935
references.citation: BMC Infect Dis. 2004 Sep 09;4:34
references.pmid: 15357874
references.citation: Virus Res. 2008 Apr;133(1):101-12
references.pmid: 17451827
references.citation: J Med Virol. 2006 Apr;78(4):417-24
references.pmid: 16482545
references.citation: Virus Res. 2005 Jan;107(1):93-101
references.pmid: 15567038
references.citation: J Immunol Methods. 2003 May 1;276(1-2):207-22
references.pmid: 12738374
references.citation: Hepatol Res. 2006 Jan;34(1):41-9
references.pmid: 16364683
references.citation: J Virol. 2005 Feb;79(4):2079-86
references.pmid: 15681410
references.citation: Biochem J. 1998 Jan 15;329 ( Pt 2):295-302
references.pmid: 9425112
references.citation: Virus Res. 2008 Apr;133(1):13-9
references.pmid: 17374415
references.citation: Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12885-90
references.pmid: 16912115
references.citation: Emerg Infect Dis. 2004 Mar;10(3):413-8
references.pmid: 15109406
references.citation: Blood. 2005 Oct 1;106(7):2366-74
references.pmid: 15860669
references.citation: J Virol. 2007 Jan;81(2):548-57
references.pmid: 17108024
references.citation: Ann N Y Acad Sci. 2007 Apr;1102:26-38
references.pmid: 17470909
references.citation: Microbiol Immunol. 2006;50(1):19-24
references.pmid: 16428869
references.citation: Novartis Found Symp. 2006;279:56-60; discussion 60-5, 216-9
references.pmid: 17278385
references.citation: World J Gastroenterol. 2005 Aug 28;11(32):5037-43
references.pmid: 16124062
references.citation: J Virol. 2005 Nov;79(21):13800-5
references.pmid: 16227300